LY317615 Plus Capecitabine in Treating Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00052273
Recruitment Status : Completed
First Posted : January 27, 2003
Last Update Posted : October 30, 2015
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Jonsson Comprehensive Cancer Center

Brief Summary:

RATIONALE: LY317615 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining LY317615 with capecitabine may kill more tumor cells.

PURPOSE: Phase I trial to study the effectiveness of combining LY317615 with capecitabine in treating patients who have advanced solid tumors.

Condition or disease Intervention/treatment Phase
Adult Solid Tumor Drug: capecitabine Drug: enzastaurin hydrochloride Phase 1

Detailed Description:


  • Determine the maximum tolerated dose and the recommended phase II dose of LY317615 and capecitabine in patients with advanced solid tumors.
  • Determine the safety profile of this regimen in these patients.
  • Determine the pharmacokinetics of this regimen in these patients.
  • Determine, preliminarily, the antitumor activity of this regimen in these patients.
  • Determine the effects of LY317615 on potential angiogenic surrogate markers in these patients.

OUTLINE: This is a dose-escalation study.

Patients receive oral LY317615 daily on days 1-14 (course 1 only). Beginning with course 2, patients receive oral LY317615 daily on days 1-21 and oral capecitabine twice daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of LY317615 and capecitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at the recommended phase II dose.

Patients are followed at 30 days after the last dose of study drug.

PROJECTED ACCRUAL: A total of 12-36 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Study With Oral LY317615 in Combination With Capecitabine in Advanced Cancer Patients
Study Start Date : December 2002
Actual Primary Completion Date : November 2004
Actual Study Completion Date : October 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed solid tumor that is refractory to standard therapy or for which no standard therapy exists
  • Measurable or evaluable disease
  • 18 and over
  • ECOG 0-2
  • Hematopoietic

    • Absolute neutrophil count at least 1,500/mm^3
    • Platelet count at least 100,000/mm^3
    • Hemoglobin at least 9 g/dL (erythrocyte transfusions allowed)
  • Hepatic

    • Bilirubin no greater than 1.5 times upper limit of normal (ULN)
    • ALT and AST no greater than 2.5 times ULN (5 times ULN if liver metastases present)
  • Renal

    • Creatinine clearance at least 50 mL/min
    • Potassium at least 3.4 mEq/L
    • Calcium at least 8.4 mg/dL
    • Magnesium at least 1.2 mEq/L
  • Cardiovascular

    • QTc interval no greater than 450 msec in males
    • QTc interval no greater than 470 msec in females
    • No other electrocardiogram abnormalities
  • Able to swallow capsules
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3-6 months after study
  • Endocrine therapy

    • At least 4 weeks since prior anticancer hormonal therapy
    • At least 6 weeks since prior bicalutamide
    • At least 4 weeks since prior flutamide or nilutamide
    • Concurrent luteinizing hormone-releasing hormone analog therapy (e.g., leuprolide or goserelin) allowed for patients with prostate cancer if started before study entry
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin).
  • Radiotherapy

    • At least 4 weeks since prior radiotherapy
    • At least 2 weeks since prior palliative radiotherapy
    • Recovered from prior therapy
  • Other

    • At least 4 weeks since prior investigational anticancer therapy
    • At least 4 weeks since other prior anticancer therapy
    • At least 30 days since prior experimental drugs

Exclusion Criteria:

  • known untreated or symptomatic CNS metastases
  • concurrent hematologic malignancies
  • gastrointestinal disorder that would interfere with oral drug absorption
  • serious concurrent systemic disorder
  • compliance issues that would preclude study
  • geographical conditions that would preclude study
  • active infection
  • prior hypersensitivity to any component of study drugs
  • pregnant or nursing
  • concurrent immunotherapy
  • concurrent routine filgrastim (G-CSF)
  • other concurrent chemotherapy
  • other concurrent hormonal therapy
  • concurrent radiotherapy (including palliative therapy)
  • other concurrent experimental medications
  • other concurrent anticancer therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00052273

United States, California
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, United States, 90095-1781
Sponsors and Collaborators
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Carolyn Britten, MD Jonsson Comprehensive Cancer Center

Responsible Party: Jonsson Comprehensive Cancer Center Identifier: NCT00052273     History of Changes
Other Study ID Numbers: CDR0000258138
P30CA016042 ( U.S. NIH Grant/Contract )
First Posted: January 27, 2003    Key Record Dates
Last Update Posted: October 30, 2015
Last Verified: August 2012

Keywords provided by Jonsson Comprehensive Cancer Center:
unspecified adult solid tumor
protocol specific

Additional relevant MeSH terms:
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents